Piribedil hydrochloride NEW
| Price | $1520 | $1980 | $2500 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-22 |
Product Details
| Product Name: Piribedil hydrochloride | CAS No.: 78213-63-5 |
| Supply Ability: 10g | Release date: 2025/07/22 |
Product Introduction
Bioactivity
| Name | Piribedil hydrochloride |
| Description | Piribedil hydrochloride can be used in the parkinson's disease, circulatory disorders, cancers research. Piribedil hydrochloride inhibits MLL1 methyltransferase activity with EC50 value of 0.18 μM. Piribedil hydrochloride is a potent and orally active agonist of dopamine D2 and dopamine D3 as well as the antagonist of α2-adrenoceptors [1] [2] [3] [4]. |
| In vitro | Piribedil hydrochloride, at concentrations ranging from 0 to 160 μM over 7 days, specifically targets and inhibits MLL1 methyltransferase activity while also selectively suppressing the proliferation of MLL-r cells, as indicated by cell proliferation assays on MLL-r AML cells (THP-1 and MV4;11) and a non-MLL leukemia cell line (K562). This compound, over a 4-day period at the same concentrations, not only selectively reduces H3K4 methylation in MLL-r cells by disrupting the MLL1-WDR5 interaction but also prompts cell-cycle arrest, apoptosis, and differentiation in these cells. Western blot analysis further reveals a concentration-dependent decrease in H3K4me2 and H3K4me3 levels, without affecting other histone methylation sites such as H3K79, H3K36, and H3K27, showcasing its selectivity and potential therapeutic implications in treating MLL-r leukemia. |
| In vivo | Piribedil hydrochloride, administered through intraperitoneal injection at doses of 5, 15, and 40 mg/kg, effectively mitigates L-DOPA-induced dyskinesias in a rat model of Parkinson’s disease. When given orally at a dosage of 4-5 mg/kg daily for two weeks, it enhances locomotor activity and reverses motor deficits in adult common marmosets. Additionally, a higher concentration of 150 mg/kg administered daily for 21 days via oral gavage has been shown to inhibit MLL-r tumor growth and reduce expression levels of MLL1 target genes in MV4;11 tumor xenografts. Studies revealed a reduction in turning behavior and various forms of dyskinesia in rats, with an increase in locomotive dyskinesias observed at the 40 mg/kg dosage. In marmosets, there was an increase in vigilance and alertness along with the reversal of downregulated preprotachykinin mRNA in the striatum, indicating improvements in motor and neurological functions. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $52.00/25mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-07-15 | |
| $283.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-06-05 | |
| $0.00/1kg |
VIP1Y
|
Chongqing Soarwin Technology Co., Ltd
|
2025-04-09 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY